Last updated on July 2019

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers


Brief description of study

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

Detailed Study Description

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). Following the dose escalation portion of the study, additional evaluable subjects may be included in order to further characterize safety and efficacy at selected doses and/or in specific patient sub-groups.

Clinical Study Identifier: NCT03212404

Find a site near you

Start Over

Research Site

Wollongong, Australia
  Connect »

Research Site

Box Hill, Australia
  Connect »

Research Site

Malvern, Australia
  Connect »

Research Site

Christchurch, New Zealand
  Connect »

Research Site

Hat Yai, Thailand
  Connect »

Research Site

Bangkok, Thailand
  Connect »